Carotid Doppler ultrasonographic findings of dapagliflozin use in type 2 diabetic patients

Basit Öğe Kaydı
dc.authoridArikan, Ali Ahmet/0000-0002-9599-1577
dc.authoridGOKOSMANOGLU, FEYZI/0000-0002-6432-8668
dc.authoridOnmez, Attila/0000-0002-7188-7388
dc.authorwosidOnmez, Attila/AAL-2984-2020
dc.authorwosidArikan, Ali Ahmet/AAA-1121-2020
dc.contributor.authorOnmez, Attila
dc.contributor.authorGokosmanoglu, Feyzi
dc.contributor.authorBaycelebi, Gulsah
dc.contributor.authorArikan, Ali Ahmet
dc.date.accessioned2021-12-01T18:50:25Z
dc.date.available2021-12-01T18:50:25Z
dc.date.issued2021
dc.department[Belirlenecek]en_US
dc.description.abstractAim: Sodium-glucose cotransporter 2 inhibitors have been shown to reduce the risk of cardiovascular disease in type 2 diabetes (T2DM) patients. The purpose of this study was to evaluate cardiovascular disease risk indirectly through Doppler ultrasonography (USG) of carotid artery vascular markers in T2DM patients using dapagliflozin. Methods: One hundred forty-five patients presenting to our clinic between March 2016 and June 2018 and diagnosed with T2DM were included in the study. These were divided into two groups - a dapagliflozin group of 85 patients and a 60-member non-dapagliflozin control group. Common carotid artery end-diastolic velocity (EDV), peak systolic velocity (PSV), and resistive index (RI) parameters were evaluated using Doppler USG in both groups. Results: The mean duration of follow-up was 2.2 +/- 0.4 years. Mean ages were 45 +/- 14 years in the dapagliflozin group and 42 +/- 15 in the control group. Mean HbA1c was 7.4 +/- 1.6 in the dapagliflozin group and 7.3 +/- 2.1 in the control group. Common carotid artery, PSV, and EDV parameters were higher (p = .012/p = .036), while RI was lower (p < .001), in the dapagliflozin group than in the control group. Conclusion: Vascular resistance was lower in the group using dapagliflozin for diabetes management.en_US
dc.identifier.doi10.1080/13685538.2020.1758657
dc.identifier.endpage1250en_US
dc.identifier.issn1368-5538
dc.identifier.issn1473-0790
dc.identifier.issue5en_US
dc.identifier.pmid32342718en_US
dc.identifier.scopus2-s2.0-85084268581en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1246en_US
dc.identifier.urihttps://doi.org/10.1080/13685538.2020.1758657
dc.identifier.urihttps://hdl.handle.net/20.500.12684/10875
dc.identifier.volume23en_US
dc.identifier.wosWOS:000532018500001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofAging Maleen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDapagliflozinen_US
dc.subjectend-diastolic velocityen_US
dc.subjectresistive indexen_US
dc.subjectcarotid Doppleren_US
dc.subjecttype 2 diabetesen_US
dc.subjectEndothelial Functionen_US
dc.subjectMetabolic Syndromeen_US
dc.subjectArteryen_US
dc.subjectAtherosclerosisen_US
dc.subjectTestosteroneen_US
dc.subjectParametersen_US
dc.subjectInhibitorsen_US
dc.subjectImpacten_US
dc.subjectIndexen_US
dc.titleCarotid Doppler ultrasonographic findings of dapagliflozin use in type 2 diabetic patientsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
10875.pdf
Boyut:
3.32 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu